Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

During the Trading Day
178.01 +0.64 / +0.36%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
178.01 0.00 / 0.00%
 
Volume: 30.2K
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$10.9B

Company Description

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded on January 18, 2012 and is headquartered in Dublin, Ireland.

Contact Information

Jazz Pharmaceuticals Plc
Connaught House
Dublin Dublin 4
P:(531) 634-7800
Investor Relations:
(531) 634-7887

Employees

Shareholders

Mutual fund holders64.30%
Other institutional25.62%
Individual stakeholders18.46%

Top Executives

Bruce C. CozaddChairman & Chief Executive Officer
Russell J. CoxChief Operating Officer & Executive Vice President
Matthew P. YoungChief Financial Officer & Executive Vice President
Mark G. EllerSenior VP-Research & Clinical Development
Karen L. SmithChief Medical Officer & Global Head-Research

To view my watchlist

Not a member yet?

Sign up now for a free account